Nateran (Exemestane)

Exemestane, the active ingredient in Nateran, is a aromatase inhibitor presented as an oral tablet for oral use. It treats postmenopausal estrogen receptor‑positive breast cancer and is used as adjuvant endocrine therapy in hormone‑responsive disease. GNH USA supplies Nateran as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres worldwide.

Exemestane acts on estrogen‑dependent breast cancer pathways and is employed in several clinical settings. - Postmenopausal estrogen receptor‑positive breast cancer: reduces recurrence risk as adjuvant therapy after surgery. - Hormone‑responsive breast cancer: inhibits estrogen‑driven tumor growth when used in the adjuvant setting. - Advanced estrogen‑dependent breast cancer: provides disease control in metastatic patients who have progressed on other endocrine agents.

Exemestane may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Hot flashes: transient episodes of intense warmth and sweating. - Joint and muscle pain: aching in limbs or back. - Nausea or mild gastrointestinal upset. - Fatigue: persistent tiredness not relieved by rest.

Serious or Rare Side Effects: - Osteoporosis or decreased bone mineral density leading to fractures. - Deep vein thrombosis or pulmonary embolism. - Significant liver enzyme elevations indicating hepatic injury. - Severe allergic reactions such as anaphylaxis or Stevens‑Johnson syndrome.

Before initiating Exemestane, several safety considerations should be reviewed. - Pregnancy: contraindicated (Category X) – avoid use in pregnant women. - Breastfeeding: not recommended; discontinue if nursing. - Bone health: monitor bone mineral density and consider calcium/vitamin D supplementation. - Liver function: assess hepatic enzymes prior to treatment and periodically thereafter. - Drug interactions: review concomitant medications for potential interactions. - Store at room temperature below 25°C: keep in the original pack, protect from moisture.

Exemestane can interact with several medicines, requiring careful management.

Major Interactions (Avoid): - Estrogen replacement therapy: may diminish the drug’s efficacy. - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): can lower plasma concentrations of exemestane.

Moderate Interactions (Monitor Closely): - Tamoxifen: potential antagonistic effect on estrogen blockade. - Anticoagulants (e.g., warfarin): may increase bleeding risk. - CYP2C19 inhibitors (e.g., fluoxetine, fluvoxamine): could raise exemestane exposure.